- Home
- OR vs VKTX Comparison
OR vs VKTX Comparison
Compare OR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OR
- VKTX
- Stock Information
- Founded
- OR 2014
- VKTX 2012
- Country
- OR Canada
- VKTX United States
- Employees
- OR N/A
- VKTX N/A
- Industry
- OR Precious Metals
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- OR Basic Materials
- VKTX Health Care
- Exchange
- OR Nasdaq
- VKTX Nasdaq
- Market Cap
- OR 3.5B
- VKTX 3.4B
- IPO Year
- OR N/A
- VKTX 2015
- Fundamental
- Price
- OR $18.62
- VKTX $34.07
- Analyst Decision
- OR Strong Buy
- VKTX Strong Buy
- Analyst Count
- OR 1
- VKTX 14
- Target Price
- OR $22.00
- VKTX $97.29
- AVG Volume (30 Days)
- OR 659.9K
- VKTX 4.8M
- Earning Date
- OR 02-19-2025
- VKTX 02-05-2025
- Dividend Yield
- OR 0.99%
- VKTX N/A
- EPS Growth
- OR N/A
- VKTX N/A
- EPS
- OR 0.09
- VKTX N/A
- Revenue
- OR $191,157,000.00
- VKTX N/A
- Revenue This Year
- OR $42.87
- VKTX N/A
- Revenue Next Year
- OR $3.33
- VKTX $986.87
- P/E Ratio
- OR $206.83
- VKTX N/A
- Revenue Growth
- OR N/A
- VKTX N/A
- 52 Week Low
- OR $13.63
- VKTX $28.64
- 52 Week High
- OR $21.29
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- OR 41.19
- VKTX 51.41
- Support Level
- OR $19.64
- VKTX $28.90
- Resistance Level
- OR $20.50
- VKTX $34.37
- Average True Range (ATR)
- OR 0.56
- VKTX 2.37
- MACD
- OR -0.10
- VKTX 0.66
- Stochastic Oscillator
- OR 13.30
- VKTX 70.06
About OR Osisko Gold Royalties Ltd
Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. The company organizes and manages the business under two operating segments: (i) acquiring and managing precious metals and other royalties, streams and other interests, and (ii) the exploration, evaluation and development of mining projects. Geographically, it generates majority of the income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.